BRIEF published on 07/28/2025 at 07:35, 1 year 1 month ago Advicenne obtient l'autorisation de mise sur le marché de Sibnayal® en Arabie saoudite Arabie Saoudite Remboursement Advicenne ATRd Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 1 year 1 month ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Autres communiqués Advicenne obtient l’AMM et le remboursement de Sibnayal en Arabie Saoudite pour le traitement des maladies rénales rares. Collaboration avec Taïba Healthcare Arabie Saoudite Advicenne Maladies Rénales Rares AMM Sibnayal
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 1 year 1 month ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
BRIEF published on 07/25/2025 at 07:35, 1 year 1 month ago Advicenne Annonce une Croissance de 9% de son Chiffre d'Affaires pour le S1 2025 Chiffre D'affaires Croissance Advicenne Sibnayal® Marchés Pharmaceutiques
PRESS RELEASE published on 07/25/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Autres communiqués Advicenne publie un chiffre d'affaires en hausse de 9% au S1 2025, avec des ventes de Sibnayal® en progression de 17%. La société dispose de trésorerie jusqu'au 3ème trimestre 2026 Chiffre D'affaires Trésorerie Advicenne S1 2025 Sibnayal®
PRESS RELEASE published on 07/25/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 1 year 1 month ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 07/21/2025 at 20:57, 1 year 1 month ago Advicenne lève 2,6 millions d'euros pour renforcer sa capacité financière Marché Financier Augmentation De Capital Bpifrance Advicenne Maladies Rénales
Published on 09/12/2026 at 02:35, 11 hours 29 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 4 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 59 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 39 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 4 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 34 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 49 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 54 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 19 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 49 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
